Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
IONS · Nasdaq · United States · Pharmaceutical Preparations
In shortIONIS PHARMACEUTICALS INC is loss-making, burns cash and holds more cash than debt, with revenue growing (+33.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -40.4% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -40.4% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -70.8% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -13.4% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.83× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 3.60× | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -22.11× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.12 | 1/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -33.9% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 27.2% | 10/100 |
| Operating margin volatility | 26.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 17.1% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 810 | 587 | 788 | 705 | 944 |
| Cost of revenue | 11 | 14 | 9.1 | 11 | 16 |
| Gross profit | 800 | 573 | 779 | 694 | 928 |
| Research & development | 638 | – | 900 | 902 | 916 |
| Selling, general & admin | 186 | 150 | 233 | 267 | 394 |
| Operating income | (30) | (410) | (354) | (475) | (382) |
| Interest expense | 9.3 | 8.1 | 13 | 17 | 17 |
| Pre-tax income | (29) | (258) | (334) | (460) | (380) |
| Income tax | (0.6) | 12 | 32 | (6.2) | 1.8 |
| Net income | (29) | (270) | (366) | (454) | (381) |
| Diluted EPS | −$0.20 | −$1.90 | −$2.56 | −$3.04 | −$2.38 |
| Diluted shares (millions) | 141 | 142 | 143 | 150 | 160 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
1.12 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: . Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Jun 30, 2026 · Data updated Jul 29, 2026